New therapies are being developed to disrupt these suppressive interactions, such as antibodies blocking other checkpoint pairs like TIM-3 and LAG3, or drugs reprogramming macrophage-tumor cell crosstalk like blocking CSF1-CSF1R signaling that recruits tumor-associated macrophages. The gene discussed is HAVCR2; the disease is neoplasm.